We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Home Urine Collection for More Accurate Prostate Cancer Detection

By LabMedica International staff writers
Posted on 09 Dec 2019
Print article
Image: Micrograph showing a prostate cancer (conventional adenocarcinoma) with perineural invasion (Photo courtesy of Wikimedia Commons)
Image: Micrograph showing a prostate cancer (conventional adenocarcinoma) with perineural invasion (Photo courtesy of Wikimedia Commons)
A standardized sampling system enables men being tested for prostate cancer to collect a urine sample at home and mail it to a laboratory for analysis.

Currently, patient urine samples are collected after a digital rectal examination (DRE) of the prostate, which was thought necessary to boost the levels of prostatic secretions in the urine. The creators of the PUR (Prostate Urine Risk) test now report the development of a sampling system that provides indication of prostate cancer risk in urine samples collected at home, eliminating a visit to the clinic and the uncomfortable rectal examination.

The PUR test was established following evaluation of the cell-free expression of 167 genes in urine samples. Investigators at the University of East Anglia (Norwich, United Kingdom) identified a mathematical combination of 35 different genes that could be used to generate four prostate urine risk (PUR) signatures for predicting the probability of normal tissue (PUR-1), D'Amico low-risk (PUR-2), intermediate-risk (PUR-3), and high-risk (PUR-4) prostate cancer. Results revealed that application of PUR provided a net benefit over current clinical practice, since each PUR signature was significantly associated with its corresponding clinical category. Furthermore, PUR-4 status predicted the presence of clinically significant intermediate- or high-risk disease.

The investigators now describe an At Home Collection Kit that allows urine to be collected by patients at home and then posted to a laboratory for analysis by PUR methodology. The collection tubes contained a commercial preservative, which allowed samples to be maintained at room temperature without loss of RNA quality. A group of 14 participants were provided with an At Home Collection Kit, and instructions. Results of their home urine samples, taken first thing in the morning were compared to samples collected after a digital rectal examination.

At the laboratory, harvest of cell-free RNA using a novel high-volume vacuum extraction method increased total RNA yields, improved the detection sensitivity of prostate-cancer-specific transcripts by RT-PCR, and enabled extraction of RNA from historic frozen urine samples. Thus, RNA yields and quality were comparable to those for post digital rectal examination urine.

The investigators suggested that this method also has the potential to be adapted for the development of home-collection tests for bladder or kidney cancer.

Senior author Dr Jeremy Clark, a senior researcher at the University of East Anglia, said, "Prostate cancer is the most common cancer in men in the United Kingdom. It usually develops slowly and the majority of cancers will not require treatment in a man's lifetime. However, doctors struggle to predict which tumors will become aggressive, making it hard to decide on treatment for many men. The most commonly used tests for prostate cancer include blood tests, a physical examination known as a digital rectal examination (DRE), an MRI scan or a biopsy. We developed the PUR test, which looks at gene expression in urine samples and provides vital information about whether a cancer is aggressive or “low risk”. Because the prostate is constantly secreting, the collection of urine from men's first urination of the day means that the biomarker levels from the prostate are much higher and more consistent, so this is a great improvement. Being able to simply provide a urine sample at home and post a sample off for analysis could really revolutionize diagnosis. It means that men would not have to undergo a digital rectal examination, so it would be much less stressful and should result in a lot more patients being tested."

The At Home Collection Kit for prostate urinalysis was described in the November 29, 2019, online edition of the journal BioTechniques.

Related Links:
University of East Anglia

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2
New
Centrifuge
Hematocrit Centrifuge 7511M4

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.